Search

Your search keyword '"Loseto, F."' showing total 3 results
Start Over Author "Loseto, F." Journal anticancer research
3 results on '"Loseto, F."'

1. Interaction of RuCl2 (dimethylsulphoxide)4 isomers with DNA.

Author

Loseto F, Alessio E, Mestroni G, Lacidogna G, Nassi A, Giordano D, and Coluccia M

Subjects
Base Sequence, DNA Restriction Enzymes antagonists & inhibitors, Molecular Sequence Data, Restriction Mapping, DNA Restriction Enzymes metabolism, DNA, Bacterial chemistry, Dimethyl Sulfoxide analysis, Plasmids
Abstract

A wide series of restriction enzymes with a range of specificities was used to investigate the interaction with DNA of Ru(II)-DMSO complexes with anticancer activity. While cis-RuCl2 (DMSO)4 was almost completely inactive, treatment of pBR 322 DNA with trans-RuCl2 (DMSO)4 protected G rich sequences from cutting of specific restriction endonucleases, indicating a preferential interaction with adjacent guanines.

Published
1991

2. Synthesis, mutagenicity, binding to pBR 322 DNA and antitumour activity of platinum(II) complexes with ethambutol.

Author

Coluccia M, Fanizzi FP, Giannini G, Giordano D, Intini FP, Lacidogna G, Loseto F, Mariggio MA, Nassi A, and Natile G

Subjects
Animals, Binding Sites, Ethambutol chemical synthesis, Ethambutol therapeutic use, Male, Mice, Mice, Inbred C57BL, Mice, Inbred DBA, Mice, Inbred Strains, Molecular Structure, Mutagenicity Tests, Organoplatinum Compounds chemical synthesis, Organoplatinum Compounds therapeutic use, Restriction Mapping, Salmonella typhimurium drug effects, Antineoplastic Agents therapeutic use, Cisplatin pharmacology, Ethambutol analogs & derivatives, Ethambutol pharmacology, Leukemia P388 drug therapy, Lung Neoplasms drug therapy, Mutagens pharmacology, Organoplatinum Compounds pharmacology, Plasmids
Abstract

Platinum complexes with N,N'-bis(1-hydroxybut-2-yl)ethylenediamine, [PtCl2(ethambutol)] were prepared and the biological activity of three isomers [with (-), (+) and (+/-) ethambutol, respectively] investigated. All species interact with the Bam HI and Ava I recognition sequences showing a binding preference for GC rich sequences of DNA. The complex which showed the greatest interaction with adjacent guanines, [PtCl2[+/-)ethambutol)] was also found to be the most mutagenic of the three. On the other hand, only [PtCl2[+)ethambutol)] had a considerable antitumour activity against both P388 leukaemia and Lewis lung carcinoma, and this was not correlated either with restriction enzyme blocking activity or with mutagenicity.

Published
1991

3. Different binding to DNA of enantiomeric platinum complexes assessed by inhibition of restriction enzyme activity.

Author

Coluccia M, Giordano D, Loseto F, Intini FP, Maresca L, and Natile G

Subjects
Cisplatin metabolism, Organoplatinum Compounds metabolism, Platinum pharmacology, Stereoisomerism, Antineoplastic Agents metabolism, DNA metabolism, DNA Restriction Enzymes antagonists & inhibitors, Platinum metabolism
Abstract

The ability of enantiomeric platinum complexes to block the action of selected restriction enzymes has been investigated. The complexes [PtCl2(DAC)], [PtCl2(DAB)] and [PtCl2(DAP)] (DAC = 1,2-diamminocyclohexane; DAB = 2,3-diamminobutane; DAP = 1,2-diamminopropane) exhibit a guanine-cytosine preference in accord with previous results on cis-[PtCl2(NH3)2] (cis-DDP). The extent of inhibition, however, is significantly different for the different isomers; the R,R form is more active than the others at short incubation time, as the time becomes longer, the differences among isomers level off. It also appears that cis-DDP is more active than [PtCl2(DAC)] in blocking the Cfo I enzyme, though it shows a preference for the G-X-G sequences.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results